Clinical trials bring the most advanced treatments to this area.

Thompson participates in clinical trials of new cancer-fighting medicines and treatments. Current trials include new therapies for cancers including breast, colon, lung, gastrointestinal, prostate, melanoma, lymphoma, leukemia, and multiple myeloma.

Call the Clinical Trials Office at 541-1812 for more information

Open trials

Brain
CTSU N0574	Whole Brain Radiation Therapy plus Stereotactic Radiosurgery (Gamma Knife) for Cancer Spread to the Brain.
RTOG 0320	Whole Brain Radiation Therapy and Stereotactic Radiosurgery (Gamma Knife) Alone versus Temozolomide or Tarceva for Non-Small Cell Lung Cancer Spread to the Brain..
Breast
CALGB 40502	First Line Treatment for Women With Locally Recurrent or Metastatic Breast Cancer with Weekly Taxol vs. Abraxane vs. Ixabepilone combined with Avastin
CTSU ECOG PACCT-1	Trial Assigning Individualized Options for Treatment of early stage Breast Cancer. Examines Tissue to Determine Risk of Recurrence and Most Appropriate and Effective Treatment (Hormonal treatment vs. Chemotherapy + Hormonal Treatment)
CTSU E1105	First Line Treatment For Women With Locally Advanced or Metastatic Her2 Positive Breast Cancer With Chemotherapy (Taxol or Taxol + Carboplatin) + Herceptin ± Avastin
CTSU E5103	Treatment For Node Positive or High Risk Node Negative, Her2 Negative Invasive Breast Cancer (Adriamycin + Cytoxan followed by weekly Taxol ± Avastin)
IBCSG 24-02 SOFT TRIAL	Trial of Suppression of Ovarian Function in Premenopausal Women With Hormone Receptor Positive Breast Cancer: Tamoxifen vs. Ovarian Suppression + Tamoxifen vs. Ovarian Suppression + Exemestane
NSABP B-39/RTOG 0413	Conventional Whole Breast Irradiation versus Partial Breast Irradiation for early stage Breast Cancer.
NSABP B-40	Preoperative Treatment For Palpable/Operable Her2 Negative Breast Cancer: Chemotherapy ± Avastin (Taxotere vs. Taxotere + Xeloda vs. Taxotere + Gemzar)
NSABP B-41	Pre-operative treatment for Palpable/Operable Her-2 Positive Breast Cancer: Chemotherapy plus Herceptin ± Tykerb (Adriamycin + Cytoxan followed by weekly Taxol with Herceptin, Tykerb, or both)
NSABP B-42	Additional Letrozole in Treating Postmenopausal Women with Hormone Receptor Positive Cancer After Completing Initial 5 years of Hormonal Treatment
NSABP B-43	Treatment for DCIS (Ductal Carcinoma in situ) after having a Lumpectomy
NSABP B-44	Treatment For Her2 positive, Node Positive or High Risk Node Negative Breast Cancer With Chemotherapy (Taxotere & Carboplatin) + Herceptin ± Avastin
Pfizer A6181077	Sutent Versus Standard Chemotherapy For Patients With Previously Treated Advanced, Triple Receptor Negative (Hormone receptor and HER2 negative) Breast Cancer
Wyeth 3003	Treatment for HER2+, Locally Advanced or Metastatic Breast Cancer with Neratinib vs. Tykerb + Xeloda
Colorectal
CTSU C80405	Trial of Chemotherapy (FOLFOX or FOLFIRI) ± Cetuximab or ± Bevacizumab or Combination of Avastin + Cetuximab With Chemotherapy
CTSU E5202	Tissue Evaluation With Treatment Based on Risk of Recurrence: Observation vs. FOLFOX ± Avastin in Stage II, High-risk, Colon Cancer
CTSU E5204	Postoperative Chemotherapy (FOLFOX ± Avastin) plus Radiation Therapy for Stage II or Stage III Patients Receiving Preoperative Chemotherapy and Radiation Therapy
CTSU N0147	Trial of chemotherapy (FOLFOX) ± Cetuximab after Curative Resection for patients with Stage III Colon Cancer
NSABP R-04	Preoperative Radiation plus Chemotherapy (5FU ± Oxaliplatin vs. Xeloda ± Oxaliplatin) for Treatment of Patients with Operable Cancer of the Rectum
Gastrointestinal
CTSU C80101	Compares Chemotherapy and Radiation Therapy for Treatment of completely resected Gastric or Gastroesphogeal Cancer
RTOG 0436	First Line Treatment for Esophageal Cancer That is Not Treated With Surgery Using Weekly Chemotherapy + Radiation ± Targeted therapy (Taxol +Cisplatin + Radiation ± Cetuximab)
GIST
SWOG S0502	Treatment with Gleevec ± Avastin For Patients with Metastatic or Unresectable GIST (Gastrointestinal Stromal Tumor)
Genitourinary
CTSU E2804	Treatment with Avastin, Nexavar, or Temsirolimus alone or in Combination For Advanced Renal Cell Carcinoma
CTSU E2805	Trial of Sutent, Nexavar, or Placebo For Surgically Removed Renal Cell Carcinoma (T1b (Grade3-4), T2-T4)
RTOG 0415	Hypofractionated 3D-CRT/IMRT Radiation Therapy Versus Conventional 3D-CRT/IMRT Radiation Therapy in Patients With Favorable-Risk Prostate Cancer
RTOG 0521	Trial of Androgen Suppression (AS) and Radiation Therapy or IMRT versus AS and Radiation Therapy or IMRT followed by Chemotherapy (Taxotere) for Localized High-Risk Prostate Cancer
SWOG 0421	First line treatment for Hormone Refractory Advanced Prostate Cancer With Chemotherapy (Taxotere) ± Study Drug (Atrasentan)
Lung, Non-Small Cell
CTSU E1505	Compares Chemotherapy (Cisplatin based) ± Avastin for Patients with Completely Resected Stage 1B non-small cell lung cancer.
Pfizer A4021016	First Line Chemotherapy (Taxol + Carboplatin) ± Investigational Study Drug (CP-751,871) for Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RTOG 0617	Compares Standard versus High-Dose Radiotherapy plus Chemotherapy (Taxol + Carboplatin) in Stage IIIA/IIIB Non-Small Lung Cancer.
SWOG 0424	Tissue & Blood Molecular Epidemiology Study for Patients With Stage I - IIIB Non-Small Cell Lung Cancer
Lung, Small Cell
CALGB 30610	Comparison of Radiation regimens in Patients with Limited Small Cell Lung Cancer also receiving Chemotherapy (Cisplatin + VP-16)
Head and Neck
	None available at this time.
Lymphoma
	None Available at this Time
Melanoma
BMS CA184-045	Compassionate Use Study of Ipilimumab For Stage III or IV Melanoma.
ECOG E1697	Four weeks of High Dose Interferon -a2B vs. Observation in Early Stage Melanoma (Stage T2b N0, T3a-b N0, and T1-4, N1a-2a)
Multiple Myeloma
SWOG 0115	Treatment with Modified High Dose Melphalan/Peripheral Bone Marrow Stem Cell Transplant in patients with Multiple Myeloma (Greater than or Equal to Age 70 or Poor Renal Function)